|
|
Article: Plenty More Behind Lead Drug.(Sirion Therapeutics Inc.)
- Article from:
- BIOWORLD Today
- Article date:
- April 10, 2007
- Author:
CopyrightCOPYRIGHT 2007 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Sirion Series B Raises $45M For Phase III Ophthalmic Bid, , By Randall Osborne, West Coast Editor
Ophthalmics-targeted Sirion Therapeutics Inc. pulled down $45 million in a Series B financing to boost a pipeline led by ST-601, the Phase III emulsion acquired last year for inflamed eyes.
"If all of our trials go well, this [cash] should get us to three new drug applications," said Todd Creech, vice president of finance for Tampa, Fla.-based Sirion, adding that the cash is expected to take the company into 2009.
Sirion started enrolling patients in January in two Phase III trials with ST-601 (difluprednate) for postsurgical use, gained in ...